This is the text extract for Consultation on proposed changes to Section H. Closed, browse documents here.

12 October 2009

Proposal to change the format of Section H

PHARMAC is seeking feedback on a proposal to change the format of Section H for Hospital Pharmaceuticals of the Pharmaceutical Schedule. In summary, this proposal would result in: 1. no longer listing specific DV Pharmaceuticals in Part II; 2. the Hospital Supply Status Products table in Part II being deleted; 3. the section Part II – Pharmaceuticals Under National Contracts being formatted the same as Sections B, C and D of the Community Pharmaceutical Schedule (see attached example); and 4. the section Part III – Assessed Pharmaceuticals being deleted. These changes are being considered as part of a project to publish Section H as an XML file that can be imported into DHB systems. The same XML file would be used in typesetting the printed version. Feedback sought PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Friday, 30 October 2009 to: Rachel Mackay Manager, Schedule and Contracts PHARMAC PO Box 10 254 Wellington 6143 Email: Rachel.mackay@pharmac.govt.nz Fax: 04 460 4995

Details of the proposal

Removal of DV Pharmaceuticals Unfortunately there is no robust process for including these items as we simply do not know everything that is available, and it changes over time. This can be misleading, as the list may not be comprehensive. The General Rules would be amended as follows:

“DV Pharmaceutical” means a discretionary variance Pharmaceutical, that does not have HSS and which: (a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or (b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.

Deletion of Part II - HSS Products table The material in this section (including expiry dates) will be presented in Part II – Pharmaceuticals Under National Contracts, which has the same alphabetic organisation. Reformatting Part II – Pharmaceuticals Under National Contracts This will make the format of this section consistent with Sections B, C and D of the Community Pharmaceutical Schedule and may facilitate the two publications being combined in future. An draft example page has been attached. Deletion of Part III – Assessed Pharmaceuticals This material is available from other sources including the PHARMAC website. A313068 Page 1 of 1

SECTION H: Pharmaceuticals Under National Contracts

Price (ex man. excl. GST) � Brand or Generic Manufacturer

Per

ABACAVIR SULPHATE WITH LAMIVUDINE Tab 600 mg with lamivudine 300 mg ..............................................630.00 ABCIXIMAB Inj 10 mg .........................................................................................579.53 ACARBOSE Tab 50 mg – 1% DV limit from Jul-09 to Jun-12................................16.50 Tab 100 mg – 1% DV limit from Jul-09 to Jun-12..............................26.70 ACETAZOLAMIDE Tab 250 mg – 1% DV limit from Dec-08 to Jun-11............................10.40 ACETYLCYSTEINE Inj 200 mg per ml, 10 ml .................................................................219.75 ACICLOVIR Tab dispersible 200 mg .......................................................................1.98 Tab dispersible 400mg ........................................................................6.64 Tab dispersible 800mg ........................................................................7.38 Inj 25 mg per ml, 10 ml .....................................................................28.72 ACITRETIN Cap 10 mg ........................................................................................75.80 Cap 25 mg ......................................................................................162.96 ACTIVATED CHARCOAL Oral liq 50 g per 250 ml ....................................................................43.50 ADALIMUMAB Inj 40 mg per 0.8 ml prefilled syringe ..........................................1,799.92 Inj 40 mg per ml 0.8 ml prefilled pen ...........................................1,799.92 ADEFOVIR DIPIVOXIL Tab 10 mg .......................................................................................670.00 ADRENALINE Inj 1 in 1,000, 1 ml ..............................................................................4.98 5.25 Inj 1 in 10,000, 10 ml ........................................................................27.00 ALENDRONATE SODIUM WITH CHOLECALCIFEROL Tab 70 mg with cholecalciferol 5,600 iu ............................................35.91 Tab 70 mg with cholecalciferol 2,800 iu ............................................35.91 ALENDRONATE SODIUM Tab 70 mg .........................................................................................35.91 Tab 40 mg .......................................................................................133.00 ALFACALCIDIOL Cap 0.25 µg ......................................................................................26.32 Cap 1 µg ...........................................................................................87.98 ALLOPURINOL Tab 100 mg – 1% DV limit from Mar-09 to Jun-11..............................5.44 Tab 300 mg – 1% DV limit from Mar-09 to Jun-11..............................4.03 ALPROSTADIL Inj 0.5 mg per ml, 1 ml – 1% DV limit from Sep-09 to Jun-11 .........1,417.50

30 1 90 90 100 10

Kivexa ReoPro Glucobay Glucobay Diamox Martindale Acetylcysteine Lovir Lovir Lovir Mayne Neotigason Neotigason Carbosorb-X Humira HumiraPen Hepsera Aspen Adrenaline Mayne Mayne Fosamax Plus Fosamax Plus Fosamax Fosamax One-Alpha One-Alpha Apo-Allopurinol Apo-Allopurinol Prostin VR

25 56 35 5 100 100 250 ml 2 2 30 5 5 4 4 4 30 100 100 250 100 5

Hospital Supply Status (Expiry date for DV limit is the last day of the month indicated)

15